Document Detail

Are there circumstances in which phase 2 study results should be practice-changing?
MedLine Citation:
PMID:  18024669     Owner:  NLM     Status:  MEDLINE    
New pharmaceuticals, innovative combinations of approved agents, and novel treatment modalities have resulted in a marked increase in the need for clinical trials. Evidence for treatment efficacy is best derived from large phase 3 randomized, controlled clinical trials. However, phase 3 investigations are lengthy and expensive, and consume patient resources. Furthermore, some diseases and treatment indications are rare, and adequate numbers of patients for a definitive phase 3 trial do not exist. Consequently, it is imperative for clinicians to understand phase 2 trial design, since their interpretation is required to apply the findings in clinical practice appropriately. The complexity of phase 2 studies is explored, including unique designs, possible use of randomization, and other key elements necessary for interpretation of phase 2 trials. Specific examples and application of these concepts are discussed in this review.
Marcie R Tomblyn; J Douglas Rizzo
Related Documents :
8393509 - The treatment of inclusion body myositis: a retrospective review and a randomized, pros...
2281229 - Adjusting for early treatment termination in comparative clinical trials.
11085349 - Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a...
17253489 - Interventions for basal cell carcinoma of the skin.
17746619 - Mathematical groups.
16205189 - Medical management of vulvar intraepithelial neoplasia.
15861079 - Pain management after lipoplasty: a study of 303 cases.
20191569 - Frequency, predictors, and prognosis of sustained minimal disease activity in an observ...
24916199 - Does fusion status after posterior lumbar interbody fusion affect patient-based qol out...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program     Volume:  -     ISSN:  1520-4391     ISO Abbreviation:  Hematology Am Soc Hematol Educ Program     Publication Date:  2007  
Date Detail:
Created Date:  2007-11-20     Completed Date:  2009-07-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100890099     Medline TA:  Hematology Am Soc Hematol Educ Program     Country:  United States    
Other Details:
Languages:  eng     Pagination:  489-92     Citation Subset:  IM    
Dept. of Hematology, Oncology & Transplantation, University of Minnesota, 420 Delaware St., SE, MMC 480, Minneapolis MN 55455, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials, Phase II as Topic*
Research Design

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Limitations of Clinical Trials in Sickle Cell Disease: A Case Study of the Multi-center Study of Hyd...
Next Document:  Trials and tribulations of systematic reviews and meta-analyses.